trending Market Intelligence /marketintelligence/en/news-insights/trending/YOMoZHw5BvP2hdvAsW16yQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Flexion's osteoarthritis drug Zilretta wins US FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Flexion's osteoarthritis drug Zilretta wins US FDA approval

The U.S. Food and Drug Administration approved Flexion Therapeutics Inc.'s non-opioid drug Zilretta, an intra-articular injection for osteoarthritis knee pain.

The FDA approval is based upon data from Flexion's pivotal phase 3 clinical trial.

Zilretta's label also includes the results from a trial that examined blood glucose concentrations in patients with type 2 diabetes. The trial found that Zilretta may avoid the spikes in blood sugar associated with the use of corticosteroid treatment in patients with both knee pain and diabetes.

Flexion expects Zilretta will be available in the U.S. by the end of October.